In fact, our data highlight the benefits of mTOR inhibition during early CD8 T cell differentiation by rescuing the terminal differentiation of lin28Tg CTLs in vitro, and enhancing tumor rejection in vivo. The gene discussed is CD8A; the disease is neoplasm.